Key Inclusion Criteria:  Presentation of GA secondary to AMD in at least 1 eye. Study eye must have the specified visual acuity (range of 84 to 4 letters; 20/20 to 20/800) using Early Treatment Diabetic Retinopathy Study charts at a starting distance of 4 meters. GA area of 0.5 to 17.76 square millimeter (~0.25 to 7 disc area) per eye measured by FAF.  Key Exclusion Criteria:  GA in either eye due to cause other than AMD. Have previously received intravitreal anti-vascular endothelial growth factor injections in study eye. Have previously received any complement/stem cell/gene therapy for any ophthalmological condition. Previous participation in interventional clinical studies for treatment of drusen, nascent GA or GA (except vitamins or minerals) irrespective of route of administration (ocular or systemic) in either eye. Presence of active ocular diseases in either eye that in the opinion of the Investigator compromises or confounds visual function or interferes with study assessments. Known or suspected complement deficiency. History or presence of any clinically relevant co-morbidities or any uncontrolled conditions. Hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients.  Note: Additional inclusion/exclusion criteria may apply, per protocol.